title: [Radiotherapy for cutaneous cancers with xeroderma pigmentosum].
abstract: OBJECTIVE
  To analyze the therapeutic results of cutaneous cancers on xeroderma pigmentosum through a series of 15 patients treated by radiotherapy.
  
  
  METHODS
  Between 1993 and 2006, 15 patients with xeroderma pigmentosum and having cutaneous cancers were treated in the Radiotherapy Department of university hospital Habib-Bourguiba of Sfax in Tunisia. Seventy-three percent of the cases occurred in male patients and the mean age of appearance of the first tumour was 18.2 years. Tumour histology was squamous cell carcinoma in 74% of the cases. The total number of cutaneous tumours was 84. Ten patients had a surgical resection. Four patients did not respond to chemotherapy. The modality of irradiation was decided according to the size, thickness and localization of the tumour. The dose of radiotherapy was 60Gy or equivalent with classic irradiation.
  
  
  RESULTS
  The total number of lesions treated with radiotherapy was 64. Forty-three lesions were treated with contact therapy, ten with brachytherapy and 11 with cobalt therapy. The following acute complications were observed: cutaneous infection (53.3% of patients), radioepithelite (80% of patients) and necroses (33.3% of patients). Evaluation after treatment showed a clinical complete remission in 73% of the cases. Late effects were noted in seven cases: telangiectasy and cutaneous atrophy. A recurrence in the irradiated zone was observed in one case. A nodal metastasis was observed in two cases. Another patient presented lung metastases. After a median follow up of 37.2 months, four patients died, seven are alive with cutaneous cancer and four are alive with complete remission.
  
  
  CONCLUSIONS
  Radiotherapy is a possible and effective therapeutic alternative. Dose and methods are not defined for xeroderma pigmentosum.
authors.affiliation: Service de radiothérapie, CHU Habib-Bourguiba, route Majida-Bouleïla, Sfax, Tunisia. ben_salah_hanen@yahoo.fr
authors.forename: H
authors.initials: H
authors.lastname: Ben Salah
authors.forename: M
authors.initials: M
authors.lastname: Bahri
authors.forename: H
authors.initials: H
authors.lastname: Turki
authors.forename: M
authors.initials: M
authors.lastname: Abdelmoula
authors.forename: M
authors.initials: M
authors.lastname: Frikha
authors.forename: J
authors.initials: J
authors.lastname: Daoud
mesh_terms: D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D001918:Brachytherapy / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics / Q000532:radiotherapy / Q000601:surgery; D002648:Child; D003037:Cobalt Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000235:genetics / Q000532:radiotherapy / Q000601:surgery; D011855:Radiodermatitis / Q000209:etiology; D011867:Radioisotope Teletherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012074:Remission Induction; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000532:radiotherapy* / Q000601:surgery; D014416:Tunisia / Q000453:epidemiology; D014983:Xeroderma Pigmentosum / Q000150:complications*; D055815:Young Adult
chemical_list: D003037:Cobalt Radioisotopes; D001761:Bleomycin; D005472:Fluorouracil